|Sample resource name||Description|
|Add-Aspirin Translational Samples||Collection of whole blood samples for plasma and DNA extraction and formulin-fixed paraffin-embedded (FFPE) tumour samples
|Apheresis MNC Collection||A cell bank of allogeneic T cells required to ensure that an adequate supply of ?? T cells is available for research and development purposes as well as to conduct future clinical trials using ?? T cells (unmodified or modified) as IMP.|
|Archival gastro-intestinal tissue, blood, saliva and urine collection||Tissue bank contains paraffin blocks, a limited number of frozen tissue samples, frozen buffy coat, plasma and serum, frozen urine and frozen saliva.|
|Arden Tissue Bank||Arden Tissue Bank operates under a Human Tissue Authority post mortem licence within a district general hospital. The biobank has generic , ethical approval and is able to collect tissues prospectively across a wide range of tissue types.
In addition the biobank has access to the full pathological archive across three hospital sites. The cellular pathology archive alone totals almost 2 million blocks, with full patient data available for the last 10 years.
|ARISTOTLE Trial||ARISTOTLE is a multicentre, phase III, randomised trial comparing standard neoadjuvant chemoradiotherapy (CRT) of oral capecitabine and radiotherapy versus standard CRT with the addition of irinotecan.
600 patients with MRI defined locally advanced, non-metastatic rectal cancer will be allocated in a 1:1 ratio to the two treatment arms.
Samples collected for translational research as part of the trial: (i) archival tumour tissue blocks (from diagnostic biopsy), (ii) tumour tissue blocks a
|AstraZeneca||AstraZeneca has a global biobank network storing human biological samples from AZ sponsored clinical trials, collaborations and also procured samples. These samples span the following main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, Respiratory, Inflammation and AutoImmunity, Neuroscience. There are over 1 million samples logged in the AstraZeneca Biobank Application (ABBA). Work needs to be done to identify which specific sample sets can be shared (both from closed clinical|
|Avon Longitudinal Study of Parents and Children (ALSPAC)||The Avon Longitudinal Study of Parents and Children (ALSPAC) is a longitudinal cohort study which has been charting the health of 14,500 families in the Bristol area since the early 1990s in order to improve the health of future generations. The study is also known as the Children of the 90s study.
Mothers were recruited during pregnancy. The children born in 1991 and 1992 (known as ALSPAC-G1) and their mothers and fathers (G0) have been followed since. A large amount of phenotypic and enviro
|Baby Bio Bank||The Baby Bio Bank is a collection of over 50,000 biological samples and medical data collected fromover 2,500 pregnancies affected by recurrent miscarriage, preterm birth, intrauterine growth restriction and pre-eclampsia. We have also collected samples from pregnancies complicated with other medical conditions such as Diabetes, high BMI, hypertension, IVF, twin and a cohort of samples from uncomplicated pregnanciess.
We hold DNA, RNA, serum, plasma and whole blood from both parents and urine f
|Barts Bioresourse||The purpose of the Bart?s Bioresource was to establish a repository of generic consented patients clinically managed by Cardiac Services at Bart?s Health NHS Trust. In addition to this the consent includes the donation of human blood, tissue donation (e.g. atrial appendage or pulmonary vein tissue) for the purpose of establishing a biobank of samples for use in cardiac disease research.
The patients are informed that ?The purpose of the Bart?s Bioresource is to allow research into diseases of
|Barts Cancer Institute Breast Tissue Bank||This ground breaking initiative will see the Barts Cancer Institute and 4 other centres around the country working together as one national resource, to house the multi-million pound Breast Cancer Now Tissue Bank. Professor Louise Jones and a dedicated team head up the Tissue bank in the Barts Cancer Institute. The tissue bank includes a dedicated cell culture team, and has just established the Metastatic Bank including a Rapid Autopsy Programme.
In the coming years we will see the benefits to
|Barts CTU||We conduct research into the prevention of cancer with particular focus on preventive therapy and screening. We are involved in clinical trials and epidemiology.|
|Barts Gynae Tissue Bank||The purpose of the Barts Gynae Tissue Bank is to collect, store and share high quality tissue for translational research into gynaecological cancers.
We collect gynaecological tissues, ascites, blood and urine that have been obtained during standard diagnostic and therapeutic procedures and are surplus to pathological diagnostic requirements. Tissues are collected from both primary and metastatic gynaecological cancer as well as from non-malignant tissues obtained in the course of standard inve
|Barts Pancreas Tissue Bank||Pancreatic diseases can be very difficult to diagnose and monitor because of the location of the pancreas deep within the abdomen. Also, with the current range of tests it may not be possible (in some cases) to tell the difference between pancreatitis (inflammation of the pancreas) and other conditions such as cancer of the pancreas without surgery and direct biopsy of tissues from this organ. This project is aimed to create a research tissue bank (explained below), specifically for pancreatic d|
|BEST3 Trial||The BEST3 Trial is a Cluster Randomised Controlled Trial comparing the Cytosponge?-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care.
The following types of the samples are collected as part of the Trial methodology: ? Cytosponge? samples ? Saliva samples (TFF3-positive Cytosponge? cases) ? Endoscopic biopsy samples including gastric cardia and clinically-indicated oesophageal biopsies Cytosponge? and endoscopic biopsy samples will be further p
|Biobank for patients with retinal degenerations & dystrophies||Outer retinal disease is the most common cause of blindness in the UK. It can be caused by a variety of single gene defects, including conditions such as retinitis pigmentosa which often result in early onset blindness in childhood, whilst the risk of age related macular degeneration is caused by a variety of complex multigene defects causing visual loss in later life. Treatments are evolving for both diseases but the underlying pathogenesis and treatment of these diseases remains elusive. We|
|BioDock||Proud to be an industry leader in cryogenic storage. Our state-of-the-art facilities are based in the UK and Switzerland. Storing over 500,000 samples from over 70 different countries|
|Biology of the Human Uterus in Pregnancy and Disease Tissue Bank||This tissue bank was established to support the research of members of the Centre for Trophoblast Research at the University of Cambridge into maternal-fetal interactions during pregnancy. Because of the limited number of samples available it is not possible to supply tissues to external researchers unless in the context of a collaborative project with a member of the Centre.|
|Bloodwise Childhood Leukaemia Cell Bank||The Bloodwise Childhood Leukaemia Cell Bank is a national collection of samples from children and young people with paediatric haematological malignancies. It is very well annotated with demographic, clinical and genetic features. This annotation enables identification and curation of very rare subgroups. There is a range of sample types including viable cells and DNA from bone marrow, plasma and CSF supporting many different types of project.
The Bank is open to international as well as UK-
|BOXIT||A randomised phase III placebo-controlled trial evaluating the addition of celecoxib to standard treatment of transitional cell carcinoma of the bladder|
|BRAIN UK||BRAIN UK is a virtual brain bank which provides access to tissue already available in NHS archives as well as the provision of generic ethics. The BRAIN UK network includes 23 of 24 Neuropathology Centres across the UK.|
|BRASH Brain Tumour Bank South West, Bristol||The aim of the brain tumour bank is to provide researchers with access to rare tumour tissue from the brain and spinal cord (which is surplus to diagnostic needs).The brain tumour bank has the approval of the National Research Ethics Service and is held under the Human Tissue Authority licence at North Bristol Trust. The bank is supported and regulated by Research and Innovation, North Bristol Trust.|
|Bristol Biobank||The Bristol Biobank (funded by the David Telling Charitable Trust with stakeholders from the University of Bristol and University Hospitals NHS Foundation Trust) stores samples collected from patients and healthy volunteers for use in biomedical research. Researchers in Bristol and beyond can apply to use these samples in their research. The collection of a wide range of samples will provide a platform for research into complex conditions.
Researchers may request to deposit samples into the B
|Bristol Dental School Saliva Bank||Whole human saliva is collected from donors at the Bristol Dental School at the University of Bristol.|
|Cambridge Blood and Stem Cell Biobank||Cambridge Blood and Stem Cell Biobank collects and curates blood and blood-product derived samples from normal individuals and patients with blood and related malignancies, with particular emphasis on accessibility to purified tumour and stem cell populations from these samples. Set up in 2009, by 2016 the bank already contains over 12,000 samples, 70% from patients enrolled on research studies and clinical trials, and the remainder from cord blood donors. We specialise in bespoke fresh specimen|
|Cam-UroOnc Biorepository||The primary role of the CamUro-Onc is to consent, collect, log and store frozen tumour/normal tissues, blood and urine for use in approved research projects. The bank has been in operation since 2003 and now has an extensive collection of biosamples from urological diseases.
Type of samples collected;
- Fresh frozen and paraffin wax embedded tumour/normal tissue (where possible) from kidney, bladder and prostate.
- Matching blood and urine samples.
- Blood and urine samples collected as pa
|Cancer Group CTR Cardiff trials||Centre for Trials Research Cardiff University. Trial sample collections|
|Cancer Tissue Bank||Controlling metastasis is an essential requirement for cancer management. The current model systems pay scant attention to human biology due to scarcity of evaluable patient samples. We propose an expansion of the tissue banks at the Barts Cancer Institute to include the collection of metastasis from a variety of primary tumours as well as distinct metastatic sites for use in laboratory research. This will facilitate identification targets to control tumour spread and develop novel biomarkers.|
|Cardamon Clinical Trial Samples||Samples taken as part of the Cardamon clinical trial|
|Cardiff School of Dentistry Tooth Bank||Collection of both deciduous and permanent teeth. Collection of fresh teeth for extraction of pulpal cells can be arranged.|
|Cardiff University Biobank||The Cardiff University Biobank is a centralised biobanking facility sited at the University Hospital of Wales. We offer high quality human biosamples for research undertaken for patient and public benefit to academic and commercial organisations. We have established collections from a number of different disease areas and welcome approaches to initiate new collections not already established within the facility. The biobank also welcome applications to deposit samples from completed research p|
|CASPS: A Phase II trial of Cediranib in ASPS patients||CASPS is a two-arm, randomised, double-blind, placebo-controlled, Phase II trial of cediranib in ASPS patients. The primary objective is to evaluate the efficacy of cediranib by measuring the percentage change in the sum of target marker lesion diameters from randomisation to week 24 compared to placebo. Secondary objectives include: progression-free survival, overall survival and safety and tolerability of cediranib in ASPS patients. Tissue markers of tumour response, circulating markers of ang|
|CEPA Biobank Newcastle||The CEPA Biobank can provide samples to both Researchers and Commercial companies on a cost recovery basis. We mainly work on a prospective collection basis, providing samples to specified instructions.|
|Children's Cancer and Leukaemia Group (CCLG) Tissue Bank||National collection of childhood, teenagers and young adults solid tumour samples and lymphomas in the UK.
Samples are centrally stored at the Central Bank, Newcastle University.
|CMFT Biobank||Our biobank is a resource for health research available to all bona-fide researchers via our application process. We hold a large collection of human biological samples with associated clinical information.
All human biological samples collected by The Biobank have full ethical approval, and is handled within the conditions of the ethical approval gained, in accordance with the requirements of the Human Tissue Act 2004 and under the governance of the Human Tissue Authority (HTA) Licence (#12
|CONFIRM Trial||CONFIRM is a double blind randomised phase III trial comparing nivolumab (anti?PD?1 antibody) monotherapy versus placebo for one year. The treatment allocation ratio is 2:1 (treatment: placebo).
|Daisy Tumour Bank||The Daisy Tumour Bank (DTB) is creating various collections of human samples to share with researchers, thus providing a resource of fit for purpose biological material to facilitate ethically approved cancer research. The DTB is collecting human tissue and blood samples from cancer patients within Hull and East Yorkshire Hospitals NHS Trust. The DTB is a newly established biobank which is in the accrual process, therefore samples and data are not accessible to researchers at this time.|
|DARWIN1 Trial||Blood and tissue from lung cancer patients|
|Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (DARWIN II)||A phase II, multi-centre, non-randomised, molecularly stratified trial for NSCLC patients to study tumour heterogeneity using genomic analysis
|DOC-MEK||A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma. The aim of this study was to assess the efficacy and safety of selumetinib combined with docetaxel as first-line treatment in patients with wild-type BRAF advanced melanoma.|
|Donate For Research Initiative (DRI)||Focusing on the procurement and supply of Fresh Biological Human samples and prospective studies. Open collaborations with other research Tissue Banks to facilitate multidisciplinary research and coordinated collections to benefit life science researchers.|
|Dr Karen Sisley||Eye tumours|
|Early Pregnancy Tissue Collection||Embryonic and fetal tissue (including placenta) collected from voluntary terminations of pregnancy|
|eLIXIR - Early Life Data Cross-Linkage in Research||The embryo, fetus and newborn child are very sensitive to external influences during development. These can arise from problems with the mother's health, her lifestyle, her physical environment, medication, the placenta not working properly, complications during birth, or as consequence of being born too early. Adversity in these periods of developmental vulnerability can have persistent effects on the long-term health of the child, including physical and mental health disorders. We also know th|
|EMR Arthritis Biobank||The EMR Arthritis Biobank provides a unique bio and data resource, with biological samples (tissue and fluids) and stringent clinical data collected from patients recruited to our various clinical trials/studies including PEAC, R4-RA, STRAP/STRAP-EU, Therapist, IRMA, PSABRE, BHSLE & TRACTISS (completed and on-going studies). Patients recruited to our studies have rheumatic conditions such as Rheumatoid, Psoriatic and Undifferentiated Arthritis, as well as auto-immune diseases such as Lupus and|
|EPHOS-B Trial||Effect of Perioperative AntiHER-2 Therapy on Early Breast Cancer Study ? Biological Phase (EPHOS-B). The EPHOS-B trial is a multicentre, three group, randomised controlled trial conducted in two parts. Part 1 (protocol versions 1 to 4): HER2+ patients were allocated in a 1:2:2 ratio to control, perioperative trastuzumab only or perioperative lapatinib only. This part of the trial will be superseded by Part 2 following the approval of amendment 5 by West Midlands - Edgbaston NRES Committee|
|Epilepsy Society Brain and Tissue Bank||The Epilepsy Society Brain and Tissue Bank is a recently established tissue bank at the Institute of Neurology, which has ethical approval and is supported by the Epilepsy Society. It is located within UCL Institute of Neurology in the Department of Neuropathology and is governed by a committee including members of the Department of Clinical and Experimental Epilepsy, the Epilepsy Society as well as SUDEP Action.
The collection comprises consented tissue samples from patients who have undergone
|ESPAC-TPlus||To centralise tissue and other clinical samples from the ESPAC studies, and make them available for future studies. Storage of the samples is designed to facilitate specific studies on response to chemotherapeutics. These separate studies will be subject to individual ethics applications. If successful they will allow subgroups of patients to be identified who will be predicted to benefit from particular chemotherapeutic regimens, improving survival for individual patients and facilitating clini|
|Ethical Tissue - University of Bradford||Ethical Tissue is a research tissue bank, licensed by the Human Tissue Authority (HTA); to collect, store and supply a wide range of human tissue, cells and fluids to biomedical research groups in academia and industry. Also includes tissue donated after death.|
|EXCEED study||EXCEED is a longitudinal population-based cohort which facilitates investigation of genetic, environmental and lifestyle-related determinants of a broad range of diseases and of multiple morbidity through data collected at baseline and via electronic healthcare record linkage.
* Recruitment has taken place in Leicester, Leicestershire and Rutland since 2013 and is ongoing, with approximately 10,000 participants aged 30-69 to date. The population of Leicester is diverse and additional recruitme
|Extracted teeth Biobank||Samples and data are donated on the basis that they will be used for the benefit of other patients and for society in general. The bank plans to maximise benefits to society by using the extracted teeth to develop improved methods of
detecting tooth decay. The caries detection rate of different methods can then be compared with the "ground truth".
which uses an histological examination of the teeth.
We propose to publicise the existence of the bank on
|Generation Scotland||A collaboration between the Universities of Edinburgh, Glasgow, Dundee and Aberdeen, and NHS Scotland, to provide resources for genetic and medical research.|
|GlaxoSmithKline Research Tissue Bank||GlaxoSmithKline R&D has a global biobank network storing human biological samples from GSK R&D sponsored clinical trials, collaborations and commercially procured samples. These samples span the following main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, Respiratory, Inflammation and AutoImmunity. There are several million samples logged in the GlaxoSmithKline R&D sample tracking systems. Work needs to be done to identify which specific sample sets can be shared (both from clo|
|GoDARTS||The GoDARTS Study has stored specimens of whole blood, serum, urine and DNA from consented patients with type 2 diabetes and matching controls (non diabetics) resident in the Tayside region of Scotland. Additionally GWAS data on ~10,000 cases is available. This resource is available to researchers worldwide to help define genetic factors related to diabetes including susceptibility, complications and response to treatment.
|GoSHARE (Genetics of the Scottish Health Research Register)|| The Scottish Health Research Register SHARE adopts an approach which asks the public to consent to their data held in NHS databases to be used to determine their suitability for research projects. Additionally participants can consent for spare blood, left after routine venepuncture to be stored for future research studies. This has been implemented in tayside and Grampian with over 50,000 blood samples intercepted by March 2017.
Anyone over the age of 11 years in Scotland can participate.
|HALT||HALT is a phase II/III, multicentre, randomised controlled trial in patients with advanced non-small cell lung cancer (NSCLC). Patients will have a defined, actionable mutation responding to targeted tyrosine kinase inhibitor (TKI) therapy and 3 or fewer sites of oligoprogressive disease, which will have developed after becoming resistant to targeted TKI treatment. 110 patients will be randomised to phase II of HALT with participants allocated to receive Stereotactic Body Radiotherapy (SBRT;73 p|
|HCV Research UK||HCV Research UK is a UK-wide consortium established in 2011 to underpin research into hepatitis C (HCV). This was achieved by establishing a biorepository and clinical research database. The biorepository is housed in the MRC-University of Glasgow Centre for Virus Research, directed by Dr John McLauchlan and managed by Dr Sarah McDonald. Samples have been obtained from around 10,000 patients.
Access to samples and data is governed by a Tissue and Data Access Committee (TDAC). These are revie
|HPB Biobank||Prospectively collected fresh tissues from surgery.
All patients fully consented.
Snap frozen paired cancers and normal tissues.
Stored in liquid nitrogen
Pancreas and ampullary cancers
1010 samples currently in bank
|Human Biomaterials Resource Centre||The HBRC is an HTA-licensed biorepository dedicated to the collection of appropriately consented high quality human biomaterials, their processing, storage and distribution to biomedical researchers. The HBRC resides within the purpose-built Advanced Therapies Facility (ATF) within the College of Medical and Dental Sciences (CMDS) at the University of Birmingham (UoB). The ATF also houses both cell and gene therapy manufacturing units.
Samples are collected, processed and stored (or released) f
|Human Developmental Biology Resource (HDBR)||The Human Developmental Biology Resource (HDBR) is an ongoing collection of human embryonic and fetal material ranging from 3 to 20 weeks of development. Material is available to researchers internationally following registration with the tissue bank. Jointly funded by the MRC and Wellcome Trust, the biobank has been operating since 1999 and is based at two centres: Institute of Genetic Medicine ? Newcastle University and the Institute of Child Health ? University College London.
|HYWEL DDA BIOBANK||This is a University Health Board Biobank initially concentrating on lung and breast material but will expand to other specialities in the future..|
|ICHTB||Human tissue bank holding samples in a variety of different formats at Imperial College London|
|ICON9 Trial||An international phase III randomised study to evaluate the efficacy of maintenance cediranib and olaparib combination therapy or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy|
|IDRIS Trial||Phase III randomised study of immunomodulatory therapy in high risk solitary bone plasmacytoma.
IDRIS is a randomised, open label, multicentre phase III study. The aim is to investigate whether the administration of adjuvant lenalidomide and dexamethasone following standard radiotherapy treatment for SBP prevents or prolongs the time to development of further plasmacytomas or progression to myeloma, or death (whichever comes first), in patients with high-risk disease compared with RT only.
|IMPORT HIGH trial blood samples||Blood samples from patients with early stage breast cancer who received breast conserving surgery and appropriate systemic therapy and radiotherapy.|
|INCA Trial||INCA is a multicentre, randomised, phase II trial comparing IO-R-CVP with Gem-R-CVP in the first line treatment of patients with DLBCL who are not fit for anthracycline-containing chemotherapy.
132 patients will be randomised to receive either IO-R-CVP or Gem-R-CVP.
Samples collected for trial: 7ml EDTA blood sample taken at baseline; Formalin fixed paraffin embedded tumour block - both sent to HMDS, Leeds. Blood serum sample (4.9ml) taken at Baseline (between day -14 pre registration a
|Infectious Diseases BioBank at King's College London||Fractionated blood products from patients with HIV, hepatitis C viral infections and others with bacteraemias.|
|interNational Anaplastic Thyroid Cancer Tissue Bank (iNATT)||The primary objective is to establish an international anaplastic thyroid cancer tissue collection to facilitate research. Patients have the option to donate blood samples and clinical data.
Research proposals will be accepted from academic and industry research parties from the UK and internationally. All research proposals will be submitted to the multidisciplinary iNATT Steering Committee for assessment.
As the volume of tissue collected per patient is expected to be of small volume, by
|IoN Trial||IoN is a multicentre phase II/III asking is ablative radioiodine necessary for low risk differentiated thyroid cancer patients.
560 patients will be recruited and randomised 1:1 to receive radioiodine ablation or no ablation.
Samples collected during trial: Stimulated Tg blood samples for patients taken at the treatment visit, 2 months post treatment, 6-9 months post treatment and every 6 months thereafter for 5 years.
|kings college Haemato -Oncology Tissue bank||The objective of our Tissue Bank is to serve as an international bioresource to facilitate basic and translational research into the aetiology, diagnosis and prognosis of blood cancers and to pursue this aim in a manner that complies with all laws, regulations and industry standards that apply to research tissue banking.Thus, our bank is rich in material from adult patients with pre-leukaemic and bone marrow failure disorders, including myelodysplastic syndromes, aplastic anaemias and paroxysmal|
|King's Health Partners Cancer Biobank||King's Health Partners Cancer Biobank collects blood, tissue and urine samples from patients with a range of cancer types who are referred to Guy's & St Thomas' NHS Trust. The Breast Biobank alone has been providing tumour samples with matching clinico-pathological data for research studies since the 1970's. Other tumour types including lung, head and neck, prostate, UGI, bladder, colorectal, lymphoma and MPD have been added since 2008. The Biobank is accessible to both academic groups and comme|
|King's Paediatric Liver Tissue Biobank||The paediatric liver tissue bank contains samples from children with rare liver diseases taken longitudinally.|
|LBIH Biobank||The LBIH Biobank has been specifically created to provide SMEs and academic researchers with high quality biosamples, data, and analytical services. We house a vast array of biosamples, both cancerous and non-cancerous, and have the ability to collect bespoke samples and data to suit the needs of researchers. We have access to a wide variety of samples types including, but not limited to, frozen tissue, fresh tissue, blood products, urine and FFPE blocks.
The LBIH Biobank can further process
|Leeds Breast Research Tissue Bank||The Leeds Breast Research Tissue Bank (LBRTB) was established in 2010 and collects malignant and normal breast tissue and associated samples from donors consented through the Leeds Teaching Hospitals Trust. The LBRTB is based in the Leeds Institute of Cancer and Pathology on the St. James's University Hospital site and is led by Professor Valerie Speirs. The LBRTB is a founder member of the Breast Cancer Now Tissue Bank (BCNTB), a ground-breaking multi-million pound initiative linking five centr|
|Leeds Dental Institute/School of Dentistry Leeds, Skeletal Tissues Bank||Tissue bank which stores teeth.|
|Leeds Multidisciplinary Research Tissue Bank||Background:
The Leeds Biobanking and Sample Processing Lab (LBSPL) is based at St James?s University Hospital and is an important element in the Leeds Clinical Research Facility (LCRF). LBSPL is dedicated to providing a sample processing service for clinical trials, and for many biobanking activities within the University and Leeds Teaching Hospitals Trust. These currently include collections of tissue, and fluid samples such as blood and urine obtained from consented patients diagnosed with k
|Leeds NIHR Biomarker Research Tissue Bank||Background:
The Leeds NIHR Biomarker Research Tissue Bank (RTB) is part of a National Institute for Health Research (NIHR) Programme Grants for Applied Research award, focused on biomarker evaluation in selected disease areas. The RTB was established for the multicentre collection and storage of samples from patients with liver diseases recruited within a randomised controlled trial (ELUCIDATE) of a biomarker panel, renal cancer patients and patients undergoing kidney transplant.
|Leicester Institute for Lung Health Research Tissue Bank||Medical research is currently in an era in which thousands of genes, RNA molecules and proteins can be analysed in a single experiment, meaning that large numbers of potential molecular markers for disease are being identified. To validate and translate these biomarkers large series of tissue and other biosamples are required. The Leicester Institute for Lung Health (LILH) Research Tissue Bank (RTB) is intended to meet this need and to facilitate high quality research. The LILH RTB will support|
|Liverpool Musculoskeletal Biobank||The Biobank aims to facilitate musculoskeletal research. To support primarily research in the University of Liverpool. It will also support other research partners both nationally and internationally. A variety of musculoskeletal tissues are collected prospectively from consented patients undergoing both elective and trauma orthopaedic surgery. Patients demographic and medical history is obtained as well as outcome and quality of life assessment scores.
|Liverpool University Biobank||The Liverpool University Biobank (LUB) is a multi-discipline biobank set up to consolidate the existing biobanks and tissue collections enabling a centralised approach to the human tissue management and integration of research within the University of Liverpool. It will incorporate retrospective collections of stored samples and prospective collection of new material.|
|Manchester Allergy, Respiratory and Thoracic Surgery (ManARTS) Biobank||Collection of samples from patients with respiratory and allergic diseases|
|Manchester Eye Tissue Repository||Repository of post mortem donor eye tissue collected after removal of the corneas for transplantation. It has been established particularly for research into macular disease (age-related macular degeneration), but other ocular tissues have been stored frozen including peripheral retina, sclera, lens, vitreous and optic nerve. Macular tissue has been stored frozen for immunohistochemistry (by embedding in OCT) and for biochemical studies. The donor tissue had been genotyped in relation to AMD|
|Manchester Skin Health Biobank||The MSHBiobank supports a varied programme of research involving skin and hair disorders. These include chemotherapy induced alopecia, inflammatory hair diseases, other alopecia?s (androgenic alopecia, Female patter hair loss) and skin research including wound healing, psoriasis and skin-related drug side effects. Research programs will aim to provide novel, publishable basic science data and contribute to patient well-being and treatment. Skin and hair samples are stored from patients who are a|
|MDSBio||Molecular and functional characterisation of bone marrow function in normal subjects, myelodysplastic syndromes (MDS), acute myeloid leukaemia (AML) and secondary disorders of haematopoiesis|
|MesobanK||A global solution to a global problem.
Mesobank is a Research Tissue Bank dedicated to the study of mesothelioma. We provide a comprehensive sample and data set from patients with mesothelioma and support biomedical research directly concerned with asbestos related disease undertaken within the UK, EEA, USA, Canada, Australia and New Zealand.
|Molecular Investigation of Haematopoietic Malignancy Study||This study focuses on procuring diagnostic, relapse, remission and progression specimens from Haemato-Oncology patients. This allows researchers to be able to investigate the development and progression of these malignancies in addition to studies into the unique microenvironment. The tissue is stored and equipment maintained to strict guidelines to ensure quality of specimens; the vast majority as single cell suspensions.
Also available are samples from the Haemato-Oncology tissue bank whic
|MRC Brain Banks Network||The UK Brain Bank Network is an initiative, led by the MRC, to establish a coordinated national network of UK brain tissue resources (banks) for researchers to use.
The banks store post-mortem brain and central nervous system (CNS) tissue donated by the public for diagnosis and research into disorders. Advances in understanding genetics and many of the molecules that define brain function mean that more and more research questions can be answered from human brain tissue.
|Multiple Sclerosis and Parkinson's Tissue Bank||The Multiple Sclerosis and Parkinson?s Tissue Bank is a national collection of CNS tissue samples donated by individuals with multiple sclerosis (MS), Parkinson?s disease and related neuroinflammatory and neurodegenerative conditions. The Tissue Bank?s mission is to facilitate discoveries by making well-characterised human material of the highest quality readily available to the research community engaged in studies aimed at finding the cause and better treatments for MS and Parkinson?s. Further|
|Myeloma XII clinical trial samples||Samples collected from myeloma patients at first relapse registered into the Myeloma XII trial, and sent to the following central labs:
1. Central immunology laboratory, University of Birmingham - peripheral clotted blood and urine collected at various timepoints throughout the trial;
2. Haematology Malignancy Diagnostic Service (HMDS) laboratory, St James's University Hospital, Leeds - bone marrow aspirate, collected at various timepoints throughout the trial;
3. Leeds Institute of Canc
|National CJD Research & Surveillance Unit (NCJDRSU) BioResource||BioResource for human prion disorders including cerebrospinal fluid, blood, and urine.|
|National Diet and Nutrition Survey (NDNS)||A National cross sectional population based survey.
Additional data available including 4 day food diary, BP, biochemical analytes
|National Unified Renal Translational Research Enterprise (NURTuRE)||The NURTuRE project was devised to create a national kidney biobank as recommended in the UK Renal Research Strategy 2016.
Strategic Aims: To work towards achieving this NURTuRE will:
1. Create a national Kidney Bio Bank for collection and storage of biological samples from 3,000 CKD patients and up > 800 NS patients, to provide a strategic resource for fundamental and translational research.
2. Develop and implement proactive UK protocol driven cohort studies in CKD and NS to investiga
|Newcastle Biobank, Newcastle University||Newcastle Biobank is a research tissue bank within Newcastle University operating under Human Tissue Authority (HTA licence no. 12534). The biobank facilitates the collection of samples (excess to diagnostic requirement) from patients and volunteers for use in medical research. Applications are made to Newcastle Biobank to:
(1) Establish a new sample collection for use in future unspecified research;
(2) Access existing samples within the biobank.
Newcastle Biobank also accepts legacy collect
|Newcastle MRC Centre Biobank for Rare and Neuromuscular Diseases||The Newcastle MRC (Medical Research Council) Centre Biobank for Rare and Neuromuscular Disease is located at the International Centre for Life (Institute of Genetic Medicine, Newcastle University).
The MRC Centre for Neuromuscular Diseases is a partnership between Newcastle University and the UCL Institute of Child Health and Institute of Neurology, and is one of the MRC's translational research centres in the UK. The Newcastle MRC Centre Biobank and the affiliated biobank located at the Ins
|NHS Cord Blood Bank||We endeavor to minimise waste and process failure in the cord blood supply chain however, inevitably there is donated material that is surplus to clinical requirement or unsuitable for therapeutic use. We are in a unique position to supply this donated material for its own research and development, also to the NHS and to authorised external organisations for specific uses. Non Clinical Issue (NCI) operates on a cost recovery basis, We do not charge for material provided but recovers the costs of|
|NHS Grampian Biorepository||The Grampian Biorepository was developed to provide core facilities that could undertake research based around the collection, storage, analysis and distribution of human biological samples collected within NHS Grampian. The biorepository supports a range of tissue based projects. The main areas of research activity are translational research programs in colorectal cancer, lung cancer. In addition we have the following collections: orthopaedic tissues and liver samples, We have access to th|
|NHS Greater Glasgow & Clyde Bio-Repository||The NHS Greater Glasgow & Clyde Bio-repository is part of NHS Scotland NHS Research Scotland Infrastructure. There is a network of Bio-repository across Scotland designed to encourage use of tissue in research and boost availability of tissue across Scotland.
Each Bio-repository node holds the responsibility for tissue governance for local and partner Health Boards with a main focus on facilitating access to surplus diagnostic and surgical tissue for use in research.
|NICAM: Nilotinib treatment for c-KIT mutated advanced AMM||Phase II single arm study evaluating the activity of nilotinib in rare c-KIT mutated acral and mucosal melanoma (AMM). Entry into the trial is a 2 step process. Patients presenting with AMM are first registered (Step 1) for screening including confirmation of c-KIT mutation status. Eligible patients who proceed to study entry (step 2) commence treatment with nilotinib 400 mgs twice daily for as long as they continue to benefit from treatment.|
|NIHR BioResource||Panel of over 100,000 highly characterised healthy volunteers and patients with common and rare diseases, who are willing to be approached to participate in research studies investigating the links between genes, the environment, health and disease.
Volunteers who join the NIHR BioResource donate their DNA via a blood or saliva sample which is used together with other information (e.g. gender, ethnicity, health records), to match them to specific research studies. Genotyping information via
|NIHR Exeter Clinical Research Facility||NIHR Exeter Clinical Research Facility is a partnership between the University of Exeter Medical School and the Royal Devon and Exeter Foundation Trust. It is dedicated to facilitation of clinical and translational research.
We have two main collections: the Peninsula Research Bank (PRB) and the Royal Devon and Exeter Tissue Bank (RDETB).
The PRB has ethics to accept gifted samples from completed studies, and the bulk of the collection is from a dedicated biobank collection called EXTEND (the
|NIHR National Biosample Centre (UK Biocentre)||The NIHR National Biosample Centre is a not-for profit enterprise supporting NIHR funded researchers across the UK. Control and rights to all samples managed by us remains with the Investigator. We offer at scale storage and processing of bio-samples with the capacity for up to 20 million stored samples in automated storage systems. Additional capacity exists for managed freezer collections and vapour phase liquid nitrogen cryostorage. We provide automated DNA/RNA extraction/normalisation and|
|NIHR Nottingham Digestive Diseases Collection||The NIHR Nottingham Digestive Diseases Biomedical Research Unit (NDDBRU) has become the central hub to the gastroenterology and hepatology research within the partnership of University of Nottingham and Nottingham University Trust, bringing together 67 principal investigators bridging basic scientific and clinical fields. Among this large group, we have expertise in a wide range of areas, techniques and methodologies although we focus on early translational studies including pre-clinical and pha|
|NIMRAD-TRANS||A retrospective sample collection of formalin fixed paraffin embedded (FFPE) pre-treatment diagnostic biopsies from patients with Head and Neck Squamous Cell carcinoma (HNSCC) enrolled on the NIMRAD trial.|
|Northern Ireland Biobank (NIB)||Northern Ireland Biobank was established in 2010 to collect, store and distribute human samples for translational research and is primarily funded by the Northern Ireland Health and Social Care Research & Development Division of the Public Health Agency. Cancer Research UK (CR-UK), the Friends of the Cancer Centre and Prostate Cancer UK have also provided financial support. The NIB complies with approvals from both the Office of Research Ethics in Northern Ireland and HSC R&D governance to host|
|Norwich Research Park Biorepository||The NRP Biorepository is a newly developing service facilitating world leading research on the Norwich Research park, home to institutes including Quadram Biosciences, the UEA, the Norfolk and Norwich University Hospital, John Innes and the Earlham Institute. Established and funded as part of the development programme of the Park, it supports academic and commercial researchers both locally and from outside the Park in all aspects of tissue based research.|
|Nostra feasibility trial||A prospective non-randomised, multi-centre feasibility study to assess if patients with residual cancer following dual-targeted neoadjuvant chemotherapy treatment for HER2-positive, ER-negative early breast cancer can be identified by multiple ultrasound-guided tumour bed core biopsies|
|NRS Lothian Bioresource||The NRS Lothian Bioresource provides access to a wide range of characterised tissue collected in a healthcare setting for use in research.
This includes surplus material from diagnostic specimens and surgical procedures. The Bioresource Lothian can facilitate collection of the following material:
Pathology archive samples
Surplus diagnostic samples - such as blood, urine or other bodily fluids
Surplus diagnostic or surgical tissue
Bespoke collections of tissue
|Obesity Research Biobank Syndicate (ORBiS)||Bariatric surgery produces substantial, long-term weight loss with reduced morbidity and mortality. Genetics can strongly influence this response, as well as the initial propensity to obesity. Several genes have been implicated but more in-depth mechanistic studies are needed to understand how genes affect energy regulation and mediate the beneficial effects of bariatric surgery.
The Obesity Research Biobank Syndicate (ORBiS) aims to fulfil this need. It provides a comprehensive collection of
|Oncology Clinical Trials Office, University of Oxford||OCTO was established in 2002 to run trials concerned with the practical application of high quality research into innovative and effective cancer therapies and prevention strategies.
Our portfolio of trials includes a range of projects from first in human drug trials through to large Phase III clinical studies. Studies assess interventions including radiotherapy, drug combinations and novel imaging techniques.
Tumour types include: colorectal, oesophageal, melanoma, lung, breast, cervical,
|Orchid Tissue Bank||The Orchid Research Tissue Bank is a Genito-Urinary tissue bank collecting and storing samples of prostate, testis, penile, kidney and bladder cancer.
It consists of fresh frozen and formalin fixed tissue samples as well as whole blood, plasma and serum collected from patients with Genito-Urinary cancers or being investigated for malignancy.
The bank was set up with the purpose of expanding the collection of male-specific cancers; providing material for scientific research aiming to discover n
|Oxford Cell & Tissue Biobank||Biobank is located within the Oxford University Hospital NHS Foundation Trust
HTA Human Application license no 11106.
Retrieves tissue for transplantation and research from living and from deceased persons.
Tissue retrieved for Research so far includes: Brain, Spinal Cord, Heart Valve, Eyes, Testicular, Ovarian.
This Oxford Biobank service is expanding and will consider requests for retrieval of other cells and tissues
|Oxford Musculoskeletal Biobank||The Oxford Musculoskeletal Biobank (OMB) is a resource of tissue and blood samples donated by patients for use in medical research (primarily musculoskeletal). The Biobank provides a simple and efficient way to collect and store samples according to regulatory requirements, and it ensures fair access to the samples. Samples will usually be used for research studies which may contribute to increasing the knowledge and understanding of musculoskeletal diseases in order to improve diagnosis and tre|
|Oxford Radcliffe Biobank||The Oxford Radcliffe Biobank (ORB) holds a Human Tissue Authority (HTA) licence for storage of human material for research, licence number 12217. The Licence Holder is the University of Oxford and the Designated Individual (DI) is Dr Clare Verrill. The licence covers activities within Oxford, at the main site, the John Radcliffe Hospital, and at the satellite sites, Cowley Store, Churchill Hospital, Nuffield Orthopaedic Centre and Department of Pharmacology.
ORB provides infrastructure to un
|Pancreatic Cancer Research Fund Tissue Bank||The Pancreatic Cancer Research Fund Tissue Bank is the world's first national pancreas tissue bank and will accelerate research into pancreatic cancer.
The Tissue Bank is funded by the medical research charity Pancreatic Cancer Research Fund, and is a unique collaboration between the charity, Barts Cancer Institute, Queen Mary University of London and six key NHS partners throughout the UK, each renowned for its expertise in treating pancreatic cancer
|Partner Trial||Randomised, phase II/III, 3-stage trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in breast cancer patients with triple negative and/or gBRCA sub-type.|
|Penile TPF||A Phase II non-randomised multicentre trial of docetaxel, cisplatin & 5-fluorouracil chemotherapy (TPF) in locally advanced and metastatic carcinoma of the penis. 26 evaluable patients recruited to receive Docetaxel 75mg/m2 day 1, cisplatin 60mg/m2 day 1, 5-fluorouracil 750mg/m2/day (day 1-5), peated at intervals of 21 days. The primary endpoint, measured by RECIST v1, (complete remission rate + partial remission rate). Secondary endpoints are te proportion of patients with inoperable locoregion|
|PHE MOHS Ebola Biobank||During the Ebola outbreak in Sierra Leone in 2014-15, residual clinical specimens and accompanying data were collected from routine diagnostic testing in Public Health England (PHE) led laboratories. Approximately 10,000 samples of which 1,440 are positive for Ebola along with all the accompanying data have been transferred to PHE laboratories in the UK for curation by PHE.
The Ministry of Health and Sanitation in Sierra Leone (MOHS) have retained ownership of the data and materials, and are
|PHOENIX DDR-Anti-PD-L1 Trial||PHOENIX DDR/Anti-PD-L1 Trial: A pre-surgical window of opportunity and post-surgical adjuvant biomarker study of DNA damage response inhibition and/or anti-PD-L1 immunotherapy in patients with neoadjuvant chemotherapy resistant residual triple negative breast cancer|
|PHOTO Translational bladder cancer biorepository||Translational study associated with the PHOTO trial - A pragmatic randomised controlled phase III trial, investigating the efficacy transurethral
resection of bladder tumour (TURBT) using photo-dynamic diagnosis (PDD) under blue light
in intermediate and high risk non-muscle invasive bladder cancer (NMIBC). The translational study is establishing a well-characterised
cohort of patients with intermediate and
high-risk NMIBC including clinical data, urine, blood
and tumour specimens that woul
|plasmaMATCH||The UK plasma based Molecular profiling of Advanced breast cancer to inform Therapeutic Choices (plasmaMATCH) Trial:
A multiple parallel cohort, open-label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening
|Plastic and Reconstructive Surgery Skin and Tissue Bank||The Plastic and Reconstructive Surgery Skin and Tissue Bank collects samples related to a range of skin and tissue clinical conditions including normal and abnormal skin scarring, dudpuytrens disease and breast capsules.|
|POETIC: Trial of perioperative endocrine therapy ? individualising care||Primary aim: To determine whether two weeks perioperative aromatase inhibitor (AI) therapy before and after surgery improves outcome compared with standard adjuvant therapy. Eligibility: Postmenopausal women with ER/PgR positive invasive breast cancer. Trial design: Phase III, multicentre, randomised trial Target accrual: 4350 patients Patients will be allocated in a 2:1 ratio to PERIOPERATIVE THERAPY with an AI for 4 weeks (two weeks before and two weeks after surgery) or NO PERIOPERATIVE T|
|PORT Trial||Skin biopsies will be obtained from patients for translational studies to identify biomarkers of immunological response to the combination of pembrolizumab and radiotherapy in patients with advanced Cutaneous T Cell Lymphoma (CTCL).|
|POUT-T||POUT-T: The translational substudy of a phase III randomised trial of peri-operative chemotherapy versus surveillance in upper tract urothelial cancer.
The objectives of POUT-T are: to investigate the molecular pathogenesis of Upper Tract Urothelial Carcinoma (UTUC); to identify prognostic and predictive biomarkers of UTUC; and to identify diagnostic biomarkers of UTUC.
POUT-T participants are requested to provide the following specimens pre-operatively, post operatively, 6 months followin
|PTCL Biobank||An Observational Study of Peripheral T cell Lymphoma: Establishment of a Biobank and Database.
The outcome of this study will be a biobank of PTCL cases with linked clinical data and serum, saliva and plasma samples to enable assessments of treatment response and prediction of relapse.
|Public Health England Seroepidemiology Unit||The basis of the PHE (formerly the Health Protection Agency) Seroepidemiology Programme is a large collection of sera representative of the general population of England, forming a unique and valuable public health resource. The collection is stored and maintained by the Seroepidemiology Unit (SEU) at the Public Health Laboratory (PHL), Manchester.
Sera submitted to the SEU are residues of specimens submitted for diagnostic testing. They sample the population range and are anonymised prior to
|QTL Programme at MRC HGU||The QTL (Quantitative Trait Locus) programme is based at the MRC Human Genetics Unit in the University of Edinburgh. The research programme uses the unique population structures in our Scottish and Croatian cohorts to deliver biological understanding of the causes of variation in complex traits. Together, the ORCADES and VIKING biobanks contain 4,000 samples from volunteers with ancestry from the Northern Isles of Scotland, www.ed.ac.uk/viking. Collectively, the CROATIA cohorts contain 6,000 par|
|Queen Mary University of London||Prognostic Factors in Prostate Cancer for Patients Treated by Watchful Waiting, conducted by the Transatlantic Prostate Group (TAPG) is a long-term retrospective epidemiology cohort study on factors predicting clinical progression of prostate cancer.
The TAPG study started in 1999 and comprises approximately 3,300 men diagnosed with prostate cancer between 1990 and 2006. This exploratory study aims to identify prognostic markers that will more accurately predict the probability of recurrence
|QUOD - Quality in Organ Donation||Organ donation and transplant saves thousands of lives a year and could be considered one of the greatest successes in modern medicine. However, over the past decade, there has been an ever increasing need for organs throughout the UK, far surpassing the supply. This is a pattern that is predicted to worsen over the next 10 years.
As many as one in three patients on the transplant waiting list will die or become too unwell to receive a transplant as a result of this disparity.
|RAPPER||RAPPER (Radiogenomics: Assessment of Polymorphisms for Predicting the Effects of Radiotherapy) is a national radiogenomics study investigating the association between common genetic variation determined by single nucleotide polymorphisms (SNPs) and radiation toxicity.|
|RATHL Trial||RATHL is a multicentre, randomised, phase III trial comparing treatment outcome for patients with advanced Hodgkin lymphoma, using FDG-PET imaging after 2 cycles of ABVD to determine response and subsequent management.
Recruitment target: 1200 patients
Patients received 2 cycles of ABVD and then had a PET-CT scan. PET negative patients were randomised to either ABVD or AVD for a further 4 cycles. PET positive patients received either BEACOPP-14, for 4-6 cycles or BEACOPP escalated, for
|RE-AKT||A multicentre prospective, randomised, phase II interventional study in mCRPC patients previously treated with 1-2 lines of chemotherapy and at least 12 weeks of abiraterone with a safety run-in and single stage phase II expansion cohort|
|REPROCELL Europe Ltd||REPROCELL Europe Ltd is a Contract Research Organisation specialising in the use of fresh human tissues to better predict drug efficacy and safety during non-clinical drug development. We source a range of fresh healthy and diseased tissues from multiple providers, across the UK, Europe and the USA, for specific academic and pharmaceutical industry sponsored projects conducted within REPROCELL facilities. Services utilising fresh tissue include pharmacological assays, 3-D culture and induced pl|
|REQUITE||Validating Predictive Models and Biomarkers of Radiotherapy Toxicity to Reduce Side-Effects and Improve Quality of Life in Cancer Survivors. The purpose of this international study is to try to predict which patients are more likely to have side effects from radiotherapy. Funded by the European Commission FP7 HEALTH scheme.|
|Respiratory Tissue Archive||This is a collection of bronchial and nasal biopsies collected between 1989 and February 2006 from volunteers with asthma, COPD and rhinitis, and age matched controls as part of the University of Southampton's ongoing respiratory research programme.|
|RIO||Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)|
|RJAH Biobank for Studying Health and Disease||Orthopaedic tissues
Wax embedded and fresh frozen tissues of primary and secondary bone tumour and metastatic disease.
If a certain tissue types are required with the correct Ethics and consent in place these could be collected and stored at the tissue bank.
|Royal Papworth Hospital Research Tissue Bank||We collect all tissue arising from cardio-thoracic procedures, including, but not limited to: aorta, myocardium, heart valves, cardiac and peripheral vessels, lung, airways, blood vessels pulmonary,blood, sputum and tumour samples. We also provide relevant routine clinical data such as previous medical history and certain treatment details.|
|RxCelerate research biobank||Plasma and serum samples from patients with atherosclerosis and assumed healthy controls|
|Scleroderma and Raynaud's Research Bank||The Scleroderma and Raynaud's Research Bank (SRRB) consists of a Bank of blood, DNA, serum, skin biopsies, calcinosis samples and capillaroscopy and thermography images with associated clinical data. These are collected on patients with scleroderma (both systemic sclerosis spectrum disorders including localised scleroderma also termed morphoea), patients with other connective tissue diseases, patients with primary Raynaud?s phenomenon, patients with shoulder problems leading to deposition of ca|
|SCOT translational sample collection||The SCOT study enrolled more than 6000 patients over a 5 year period and is the largest single trial ever conducted in CRC. Tissues collected from patients entered in to the study are physically hosted in two sites; blood samples and blood fractions e.g. DNA, are held at the University of Oxford and FFPE samples are housed at the Glasgow Biobank. There are approximately 3000 blood and 3000 tissue samples in the collection.
The associated clinical data is held by the Cancer Research UK Clinic
|Scottish Early Rheumatoid Arthritis (SERA)||The Scottish Early Rheumatoid Arthritis (SERA) study is an inception cohort of rheumatoid (RA) and undifferentiated arthritis (UA) patients that aims to provide a contemporary description of phenotype and outcome and facilitate discovery of phenotypic and prognostic biomarkers.|
|Scottish Human Papillomavirus Archive||The Scottish HPV Archive is a biorepository of samples that provides a vital resource for researchers to improve the way we detect and manage HPV associated disease.
The archive is housed within the Queen's Medical Research Institute, University of Edinburgh, and follows the governance policies of NHS Lothian for tissue collections and the bio-repository principles of the Lothian NRS Bioresource (SAHSC).
It currently holds over 40,000 samples, the majority of which are cervical liquid-base
|Sheffield Brain Tissue Bank (SBTB)||Sheffield Brain bank comprises of tissue samples mainly of Degenerative diseases (MND, Alzhiemers)|
|Sheffield Collaborating Centre of the Breast Cancer Now Tissue Bank||The University of Sheffield collects malignant and normal breast tissue and blood samples from patients attending the Royal Hallamshire Hospital and Weston Park Hospital, Sheffield as part of a research project led by Prof. Angela Cox; "The role of angiogenesis and genome stability in breast cancer, and biosample collection". The research group specialises in the collection of longitudinal blood samples, including blood plasma for circulating DNA applications. Patients are invited to donate thei|
|Sheffield Lung Research Tissue Bank||This lung tissue research bank at the University of Sheffield supports a long-standing interest in lung cell biology. Projects have investigated aspects of lung mast cell and macrophage biology and current work is focussed on pulmonary vascular cell biology. As part of this ongoing research we have curated more than 1000 samples of ?grossly normal? lung tissue from individuals who have undergone lung surgery.|
|Sheffield Pulmonary Hypertension Biobank||Longitudinal collection of blood samples from patients with pulmonary hypertension and associated lung and cardiovascular disease, as well as some healthy volunteers as controls. The biobank samples with associated clinical data are used in research into the these conditions, how they cause symptoms and illness, and to develop new ways to diagnose, treat, and prevent diseases.|
|South Yorkshire and North Derbyshire Musculoskeletal Bio Bank||The SYNDMB collects, stores and distributes tissue samples as necessary to deliver tissue to approved research projects. This may include the collection of samples from donors with rare conditions or characteristics of special interest for use in future research that is not yet defined. The SYNDMB may accept a wide range of samples and data obtained from donors, or completed, ethically approved projects with appropriate consent for Biobank storage, in South Yorkshire and North Derbyshire, elsewh|
|St Thomas' Hospitals Plasma, serum & DNA Bio bank from patients with antiphospholipid antibodies||A frozen biobank collection of plasma, serum, and DNA from APS patients. Each sample is anonymised blood sample collected from patients who consent for its use in future research into Antiphospholipid Syndrome. APS is defined as the association of antiphospholipid antbodies (aPL) with arterial or venous thrombosis and /or pregnancy morbity. Antiphospholipid syndrome is an autoimmune disorder in which aPL are involved in the development of venous and/or arterial thrombosis.|
|SUN Study||The SUN study is a Bio repository of 6 monthly sequential blood samples from 350 men with Prostate Cancer - pre-treatment and through follow-up|
|Tayside Biorepository||Tayside Biorepository is an established bio-resource responsible for the provision of a wide range of human tissue from consenting patients in addition to providing a large range services including staining and extraction methods.|
|The Airwave Health Monitoring Tissue Bank||The Airwave Health Monitoring Study was established to evaluate possible health risks associated with the use of TETRA, a digital communication system used by the police forces and other emergency services. It is a long-term observational study following up the health of police officers and staff across Great Britain, with the ability to monitor both cancer and non-cancer health outcomes. Around 53,000 participants have been recruited between June 2004 and March 2015 with a response rate averagi|
|The Christie NHS Foundation Trust||Facilitating high quality cancer research by bringing a flexible and committed approach to ethical sample and data collection|
|The Cleft Collective||The Cleft Collective is a longitudinal cohort study looking to investigate the biological and environmental causes of cleft and the best treatments of cleft on those affected and their families. The study comprises two separate cohorts, a Birth Cohort and a 5-year-old Cohort. The birth cohort is further split into two sub-groups, postnatal and antenatal, allocation to these groups is determined by the time of recruitment. Recruitment to the two cohorts is currently ongoing across the UK. A l|
|The PEACE Study||The PEACE (Posthumous Evaluation of Advanced Cancer Environment) Study|
|The Swansea Neurology Biobank||The Swansea Neurology Biobank, (SNB) is a collaboration between Swansea University and Local Health Boards, collecting biological specimens from a range of neurological phenotypes.|
|Tissue Access for Patient Benefit (TAPb)||We aim to facilitate the pathway for access, storage, use and transfer of human organs, cells and tissue between clinical centres within UCL Partners, academic groups in UCL, other universities, hospitals, medical researcher and biotechnology companies, to enhance the ability for researchers to access the materials they need. Alongside this, researcher will be able to exchange information and access guides on regulatory, ethics and practical issues concerning access, transfer and use of this typ|
|Tissue Solutions Ltd||Tissue Solutions specializes in sourcing biological material for academics, pharma & biotech companies and CROs and is working with clients worldwide (USA, UK, Europe and Japan). We are a virtual tissue bank, working with multiple sources to acquire samples on behalf of our clients for use mainly during the preclinical research phase. We never retain tissues ourselves for our own use. We provide access to banked human tissues and set up prospective collections in the UK and USA. We specialise i|
|TNT: Triple Negative breast cancer Trial||TNT is a phase III, multi centre, randomised trial of carboplatin versus docetaxel in women with ER-, PgR- and HER2- metastatic or recurrent locally advanced breast cancer. Patients will be randomised (1:1) to carboplatin or docetaxel and will cross over to the alternative treatment (docetaxel (if randomised to carboplatin) or carboplatin (if randomised to docetaxel)) on progression. Trial Treatment: Group A: Carboplatin AUC 6, q 3 weeks for 6 cycles (18 wks) Group B: Docetaxel 100mg/m2, q 3|
|Tommy's National Reproductive Health Biobank||The Tommy's Biobank aims to prospectively collect samples from pregnant and non pregnant women to help research in to pregnancy complications. The biobank has been granted permission to ethically approve research projects conducted in the field of reproductive health. The biobank will bring together six biobanks that will all collect samples of high quality according to the standard operating procedures written by experts in the field of reproductive health.|
|TOPARP: Ph. II Trial of Olaparib in Patients with advanced CRPC||TOPARP is an open-label, single arm, two part adaptive design phase II trial of olaparib in mCRPC. Patients will receive single agent olaparib at a dose of 400 mg twice daily, continuously on a 28-day cycle, until objective disease progression or unacceptable toxicity or patient withdrawal for whatever reason.|
|TRACERx (TRAcking non-small cell lung Cancer Evolution through therapy (Rx))||A prospective observational cohort study of patients with non-small cell lung cancer (NSCLC), in which translational research is the fundamental aspect of the study.|
|TRICON8||TRICON8 is the translational research sub-study of the ICON8 trial. Its aim is to establish a large, comprehensive biobank comprising tumour tissue, blood and serial plasma samples with associated clinical data which will be an invaluable resource for high-quality translational research in ovarian cancer.
ICON8 is a phase III randomised controlled trial designed to investigate the safety and efficacy of two dose-dense, dose-fractionated, weekly carboplatin-paclitaxel combination chemotherapy
|TRICON8B||TRICON8B is the translational research sub-study of the ICON8B trial. The aim is to establish a large, comprehensive biobank comprising tumour tissue, blood and serial plasma samples with associated clinical data which will be an invaluable resource for high-quality translational research in ovarian cancer.
ICON8B is a phase III randomised trial investigating the combination of dose-fractionated chemotherapy and bevacizumab compared to either strategy alone for the first-line treatment of wo
|TwinsUK||The TwinsUK cohort, set up in 1992, is a major volunteer-based genomic epidemiology resource with longitudinal deep genomic and phenomic data from over 14,500 adult twins (18+) who are highly engaged and recallable. It is one of the most deeply characterised adult twin cohort in the world, providing a rich platform for scientists to research health and ageing longitudinally. More than 800 data access collaborations and 150,000 samples have been shared with external researchers, resulting in ~600|
|UCL / UCLH Biobank for Studying Health and Disease||The Biobank stores normal and pathological specimens, surplus to diagnostic requirements, from relevant tissues and bodily fluids. Stored tissues include; snap-frozen or cryopreserved tissue, formalin-fixed tissue, paraffin-embedded tissues, and slides prepared for histological examination. Tissues include resection specimens obtained surgically or by needle core biopsy. Bodily fluids include; whole blood, serum, plasma, urine, cerebrospinal fluid, milk, saliva and buccal smears and cytological|
|UCL Eastman Biobank||The UCL Eastman Biobank will act as a physical repository for collections of biological samples and data for research purposes from consented patients at the Eastman Dental Institute and Hospital, University College London and University College London Hospitals Foundation Trust (Eastman). This will incorporate prospective collections of stored samples and new collections. It provides a unique opportunity to advance dental and medical research by making access to tissue surplus to requirements e|
|UCL Infection DNA Bank||The UCL Infection DNA Bank aims to facilitate research into infectious diseases through the enhanced availability of samples to researchers. This availability currently supports research in the UCL Division of Infection and Immunity but it will also support researchers nationally and internationally, increasing the potential for collaboration.|
|UCL Royal Free Hospital Biobank||The physical repository was established in Nov 2009 and is located within the Royal Free London NHS Trust, London UK. The UCL-RFH Biobank provides a biorepository facility to user groups on a cost-recovery model. Types of biospecimens include Serum, Plasma, Cells, Tissue, DNA, Urine etc. In particular, samples considered 'relevant material', such as tissues and cells, which are licensed by the Human Tissue Authority (HTA), can be stored long term. Existing holdings where appropriate can be tran|
|UK Biobank||UK Biobank is a major national health resource, and a registered charity in its own right, with the aim of improving the prevention, diagnosis and treatment of a wide range of serious and life-threatening illnesses ? including cancer, heart diseases, stroke, diabetes, arthritis, osteoporosis, eye disorders, depression and forms of dementia. UK Biobank recruited 500,000 people aged between 40-69 years in 2006-2010 from across the country to take part in this project. They have undergone measures,|
|UK CLL Trials Biobank||A collection of Chronic Lymphocytic Leukaemia samples from patients on clinical trials. Includes the trials; AdMIRE, ARCTIC, CHOP-OR, CLL210, CLEAR, COSMIC, RIAltO, FLAIR|
|UK ME/CFS Biobank||Participants:
Over 650 participants are included in the study, including ME/CFS participants diagnosed by a physician and compliant with CDC ?94 (Fukuda) and Canadian Consensus Criteria (CCC), with case definition compliance available for four other commonly-used criteria. Healthy and MS matched controls are also available.
? Mild and Moderate ME/CFS
? Severe (Home-Bound) ME/CFS
? Multiple Sclerosis
? Healthy Controls
Over 32,000 aliquots available.
? Whole Bl
|UK MND Collections||The UK MND Collections (formerly known as the UK MND DNA Bank) was established to provide the international research community with a resource that would help to identify and understand the causative and disease modifying factors involved with motor neurone disease. These samples are available for research into MND and associated conditions such as fronto-temporal dementia only.
The UK MND Collections combines more than 3,000 biological samples and accompanying clinical information; as well a
|UK primary Sjogren's syndrome Registry||Peripheral blood samples (DNA, RNA, serum, PBMC) from patients with primary Sjogren's syndrome, with detailed contemporaneous clinical data at the time of sample collection.
|UK real-world lymphoid tissue bank||The UK real-world lymphoid malignancies tissue Bank (UKTB) provides a national and international resource for research on lymphomas and other lymphoproliferative disorders including chronic lymphocytic leukamia. This Research Tissue Bank was set up in 2014 and given favourable ethical opinion (REC ref: 14/SC/0030). The samples are stored in the HTA licenced Faculty of Medicine Tissue Bank. The RTB currently holds matched normal and malignant frozen material from ~900 patients. The samples collec|
|UKALL14 Trial||A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia.
Multisite, randomised controlled trial, recruiting 811 patients over 7.5 years.
Samples will be collected throughout the trial and sent to the central lab (Adult ALL MRD Lab @ UCL CI) as follows;
- bone marrow samples taken at diagnosis, at recover post phase 1 and phase 2, post transplant (for those patients who proceed with a non-myeloblative transplant) and at relapse.
- pheripheral blood sample taken durin
|Ukall60 Trial||The UKALL60+ trial is a multi-centre, prospective, non-randomised, multiple pathway trial to document the safety, tolerability and efficacy of standard ?backbone? chemotherapeutic regimens in older patients with de novo ALL.
Samples will be collected throughout the trial and sent to the central lab (Adult MRD lab at UCL CI) as follow:
1. At diagnosis (pre trial registration)
2. After Phase 1 Induction
3. After Phase 2 Induction
4. a) After Intensification (for patients on the pathway B ONL
|UKCTOCS Longitudinal Women's Cohort (UKLWC)||This is the bioresource resulting from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), one of the world?s largest randomised controlled trials. Between 2001-2005 1.2 million women aged 50-74 years were invited from the general population and 202,638 post-menopausal were randomised (2:1:1) to routine care, or annual CA125 blood testing (7-11 rounds) or ultrasound to evaluate the impact of ovarian cancer screening on disease mortality. All participants provided a seru|
|UNIRAD UK Sample collection||Randomised, double-blind, multicentre phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with high risk of relapse, ER+ and HER2- primary breast cancer who remain free of disease (UNIRAD).|
|University of Leeds||Samples collected from patients in the CALIBER trial of chemoablation versus surgical management in low risk non-muscle invasive bladder cancer|
|University of Leicester Cancer Research Biobank||The Biobank collects and stores samples for local studies. Samples collected include;
?Frozen disease-affected tissue
?Paraffin embedded disease-affected tissue
?sorted stem cells
|University of Liverpool - GCP Laboratory Facility||Combined repository of clinical trial samples for ?future use?.
Will include samples from clinical trials co-ordinated by the Liverpool Cancer Trials Unit and from studies with Liverpool Principal Investigators.
|University of Sheffield||Longitudinal blood samples from patients with suspected and confirmed pulmonary hypertension|
|University of Southampton Faculty of Medicine Tissue Bank||The Tissue Bank is licensed by the Human Tissue Authority (HTA) to source, organise, collect, prepare, store and distribute a diverse collection of human tissues and biological products.
All tissue is collected with patient consent and distributed anonymously only to National Research Ethics Service (NRES) approved studies. This valuable resource is available to aid the study of cancer biology and other associated research. The Tissue Bank allows for rapid access to a plethora of biological
|VinCaP||VinCaP is a phase II, multicentre, non-randomised trial of Vinflunine chemotherapy in locally-advanced and metastatic carcinoma of the Penis. 22 evaluable participants will be recruited from 9 centres and all patients will receive 4 cycles of IV vinflunine 320mg/m2 on day 1, to be repeated at intervals of 21 days. The primary endpoint, determined by RECIST v1.1, is clinical benefit (objective response + stable disease rate) measured after four cycles of vinflunine chemotherapy. Secondary endpoin|
|VORTEX-BIOBANK||Collection of matched tumour and normal tissue samples, FFPE blocks and EDTA blood samples from human soft tissue sarcoma (STS).|
|Wales Cancer Bank||The Wales Cancer Bank (WCB) was set up in 2004 and consented the first patient in 2005. The project is hosted by Cardiff University and receives funding from the Welsh Government, Cancer Research Wales and Velindre Charitable funds.
A Cancer Bank is literally a collection of tissue and blood which has been collected from patients where cancer is a possible diagnosis and is being stored to facilitate future research into cancer.
Statistics suggest that four out of ten people will be diagnos
|Watch and Wait Trial||Watch and Wait is a randomised phase III trial to determine whether initial treatment with rituximab in patients with advanced stage asymptomatic follicular lymphoma (grades 1, 2 and 3a) results in a significant delay in the initiation of chemotherapy or radiotherapy and the impact of each strategy on patient-related quality of life.
360 patients randomised to receive either Rituximab treatment and maintenance or to a Watch and Wait strategy.
Samples collected for trial: Formalin fixed pa
|York Tissue Bank||In collaboration with York Teaching Hospital NHS Trust, the University of York has established the York Tissue Bank: a tissue bank to help research into human disease. We aim to collect, store and build a repository of human tissue samples, such as urine, blood and tumours. These can then be given to researchers for their studies. These studies will aim to improve our understanding of human health and potentially lead to new methods of diagnosis, better treatments and vaccines for a wide range o|